Fundraising Fox
/Companies
Sign in

Vitarka Therapeutics

3 known investors

Find your way into Vitarka Therapeutics

Sign up to see every warm intro you have to Vitarka Therapeutics

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Vitarka Therapeutics team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

Vitarka Therapeutics develops ENDOPORE, a drug delivery technology designed to transport therapeutic molecules into cells to treat diseases including cancer. The company operates in the biotechnology sector, focusing on solving a key challenge in drug development by enabling treatment targets that previously could not be reached.

BiotechHealthtechMedical Devices

Founders & leadership

VTVineeta Tripathi
Vineeta TripathiFounding CEOVineeta Tripathi has over 15 years of pharmaceutical drug development experience across neuroscience, immuno-oncology, and ophthalmology, with academic expertise in neurodegenerative disease mechanisms and a track record of published research and patent inventions in therapeutic biologics. She is co-founder and CEO of Vitarka Therapeutics, a biotechnology company developing intracellular drug delivery technology.
JBJohn Beadle
John BeadleCo-founderJohn Beadle is a physician with an MD and MBA who has held leadership roles including Founding CEO of PsiOxus, Founder and Chief Medical Officer of PowderMed, Site Head at Pfizer, and VP of Global Medical Operations at GlaxoSmithKline, with experience in nucleotide vaccines, stem cell therapies, gene therapies, and immuno-oncology.

Investors · 3

SOSVlisted by SOSVNew York · $30K – $550K

How we know: funding news · open dataset · 5k.vc investor directory · sosv.com · Not right? Tell us

UK Innovation & Science Seed Fundlisted by UK Innovation & Science Seed FundManchester · $127K – $635K

How we know: UK Innovation & Science Seed Fund's portfolio page · Not right? Tell us

Companies House · registry record

View on Companies House ↗
Registered name
VITARKA THERAPEUTICS LTD
Company number
13291464
Status
Active
Company type
Private limited company
Incorporated
25 Mar 2021
Registered office
Innovation House Innovation Way, Discovery Park, Sandwich, CT13 9FF
Nature of business (SIC)
72110 — Research and experimental development on biotechnology
Accounts
last made up to 31 Dec 2025 · next due 30 Sept 2027
Confirmation statement
last made up to 24 Mar 2026 · next due 7 Apr 2027

Current officers · 4

  • John William Beadle — director, appointed 11 Nov 2024
  • James Duncan Bruce Faulkner — director, appointed 11 Mar 2024
  • Mayer Schreiber — director, appointed 5 Apr 2022
  • Vineeta Tripathi — director, appointed 25 Mar 2021

Source: Companies House public register · retrieved 23 Aug 2026. Contains public sector information licensed under the Open Government Licence v3.0.

In the news

UK biotech start-up secures £1.27M to revolutionise intracellular drug delivery through tumour targeted technology - Vitarka Therapeutics Ltdvitarka.co.uk · Apr 2023

Frequently asked questions

What does Vitarka Therapeutics do?
Vitarka Therapeutics develops ENDOPORE, a drug delivery technology designed to transport therapeutic molecules into cells to treat diseases including cancer. The company operates in the biotechnology sector, focusing on solving a key challenge in drug development by enabling treatment targets that previously could not be reached.
Who founded Vitarka Therapeutics?
Vitarka Therapeutics was founded by Vineeta Tripathi, John Beadle.
Who are Vitarka Therapeutics's investors?
Vitarka Therapeutics's investors include Future Planet Capital, SOSV, UK Innovation & Science Seed Fund.